Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DM4YWCZ)

• Drug Name: Nalmefene Drug Info
• Synonyms: Alcofene; Arthene; Cervene; Cessal; Incystene; Nalmefeno; Nalmefenum; Nalmetrene; Nalmetreno; Nalmetrenum; Revex; Soberal; JF 1; ORF 11676; JF-1; NIH-10365; Nalmefeno [INN-Spanish]; Nalmefenum [INN-Latin]; Nalmetreno [INN-Spanish]; Nalmetrenum [INN-Latin]; ORF-11676; Revex (TN); Nalmefene (USAN/INN); Nalmefene [USAN:BAN:INN]; (5alpha)-17-(Cyclopropylmethyl)-4,5-epoxy-6-methylenemorphinan-3,14-diol; (5alpha)-17-(Cyclopropylmethyl)-4,5-epoxy-6-methylenemorphinon-3,14-diol; (5alpha)-17-(cyclopropylmethyl)-6-methylidene-4,5-epoxymorphinan-3,14-diol; 17-(Cyclopropylmethyl)-4,5alpha-epoxy-6-methylenemorphinan-3,14-diol; 6-Desoxy-6-methylenenaltrexone; 9a-(Cyclopropylmethyl)-4,5alpha-epoxy-6-methylen-3,14-morphinandiol
• Therapeutic Class: Anticraving Agents
• Cross-matching ID:
  PubChem CID: 5284594
  ChEBI ID: CHEMBL982
  CAS Number: CAS 55096-26-9
  TTD Drug ID: D05VIL

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)

Term Name	NES	FDR q-val	Tag %	Leading Edge Genes
Autoimmune thyroid disease	-1.65	4.26e-2	46/53 (86.79%)	TG;CTLA4;HLA-DQB1;...
TNF signaling pathway	-1.65	4.16e-2	103/112 (91.96%)	FAS;TRAF5;CREB1;...
Type I diabetes mellitus	-1.66	3.57e-2	38/43 (88.37%)	HLA-DQB1;HLA-F;HLA-E;...
Hematopoietic cell lineage	-1.66	3.70e-2	90/99 (90.91%)	CD14;CD34;IL2RA;...
Synaptic vesicle cycle	-1.67	3.75e-2	63/78 (80.77%)	STX2;ATP6V0D1;SLC1A2;...
NF-kappa B signaling pathway	-1.69	3.13e-2	90/104 (86.54%)	BCL2L1;TICAM1;NFKB1;...
Bacterial invasion of epithelial cells	-1.70	2.91e-2	59/77 (76.62%)	RHOA;PIK3CD;CAV2;...
D-Glutamine and D-glutamate metabolism	-1.71	3.04e-2	5/5 (100%)	GLS;GLUD1;GLUD2
Taurine and hypotaurine metabolism	-1.73	2.57e-2	8/11 (72.73%)	GAD2;CDO1;BAAT;...
Graft-versus-host disease	-1.74	2.70e-2	32/42 (76.19%)	HLA-DPB1;TNF;KLRD1;...
Leukocyte transendothelial migration	-1.75	2.59e-2	90/114 (78.95%)	ACTN1;RHOA;ITGAM;...
Riboflavin metabolism	-1.75	2.54e-2	7/8 (87.5%)	ACP5;ENPP1;RFK
Toll-like receptor signaling pathway	-1.76	2.68e-2	94/104 (90.38%)	PIK3CB;IFNAR2;TICAM1;...
Leishmaniasis	-1.78	2.34e-2	67/77 (87.01%)	NFKB1;HLA-DPB1;FCGR2A;...
Apoptosis	-1.81	1.81e-2	126/168 (75%)	BCL2L1;BAD;NFKB1;...
Yersinia infection	-1.82	1.85e-2	120/137 (87.59%)	PIK3CB;IL18;TICAM1;...
VEGF signaling pathway	-1.88	9.47e-3	50/59 (84.75%)	PIK3CB;BAD;KDR;...
Rheumatoid arthritis	-1.89	1.02e-2	78/93 (83.87%)	TGFB3;TCIRG1;IL15;...
B cell receptor signaling pathway	-1.92	6.03e-3	71/81 (87.65%)	PIK3CB;NFKB1;BCL10;...
Th1 and Th2 cell differentiation	-1.93	4.38e-3	80/92 (86.96%)	MAF;STAT5B;NFKB1;...
Th17 cell differentiation	-1.93	4.82e-3	95/107 (88.79%)	IFNGR1;IL4R;NFATC1;...
TGF-beta signaling pathway	-1.94	4.02e-3	81/94 (86.17%)	PPP2CB;BAMBI;TGFB2;...
Intestinal immune network for IgA production	-1.99	3.01e-3	38/48 (79.17%)	HLA-DQB1;TNFRSF13B;CD40LG;...
Osteoclast differentiation	-2.00	3.44e-3	117/127 (92.13%)	PIK3CB;IFNAR2;NFKB1;...
Viral myocarditis	-2.01	2.01e-3	53/60 (88.33%)	SGCB;HLA-DQB1;SGCD;...
Allograft rejection	-2.01	2.41e-3	32/38 (84.21%)	HLA-DQB1;CD40LG;HLA-F;...
Cell adhesion molecules	-2.02	3.01e-3	118/148 (79.73%)	SELPLG;CDH15;CLDN7;...
Malaria	-2.03	4.02e-3	44/50 (88%)	ITGAL;THBS4;TGFB2;...
T cell receptor signaling pathway	-2.04	6.03e-3	93/104 (89.42%)	NFKB1;BCL10;MAPK10;...
Primary immunodeficiency	-2.05	1.21e-2	33/38 (86.84%)	PTPRC;CD19;CD3E;...

Pharmacogenomic Perturbation Across Diseases and Tissues

Prostate

Prostate carcinoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
PC-3	CVCL_0035	Homo sapiens	1.11uM - 10uM	24H	Hide ▲

Skin

Melanoma

Cell Line Name	Cellosaurus Accession	Species of Origin	Drug Dosage	Time Point	Details
A-375	CVCL_0132	Homo sapiens	1.11uM - 10uM	24H	Hide ▲